Trial Profile
Intravitreal Ranibizumab (Lucentis) for Neovascular Glaucoma- a Randomized Controlled Study
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Neovascular glaucoma
- Focus Therapeutic Use
- 30 Sep 2016 New trial record